Recent advances in the neuropsychopharmacology of serotonergic hallucinogens - Test2 - elhamkhani - TriplyDB

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

http://www.wikidata.org/entity/Q27027381

about

Neural correlates of the LSD experience revealed by multimodal neuroimaging Lysergic acid diethylamide: a drug of 'use'?Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.Psychedelics Modern Clinical Research on LSD.Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced Ego Dissolution.Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin.Behavioral Effects of Systemic, Infralimbic and Prelimbic Injections of a Serotonin 5-HT2A Antagonist in Carioca High- and Low-Conditioned Freezing Rats.Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)Neuropharmacology of N,N-dimethyltryptamine Clinical applications of hallucinogens: A review.The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens.Novel psychoactive substances of interest for psychiatry.Tolerance and cross-tolerance to head twitch behavior elicited by phenethylamine- and tryptamine-derived hallucinogens in mice.Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats.Serotonin and brain function: a tale of two receptors Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation.The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens.Psychedelics Recruit Multiple Cellular Types and Produce Complex Transcriptional Responses Within the Brain.Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways.Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives.Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain.5-HT2A Agonists: A Novel Therapy for Functional Neurological Disorders?Effect of 5-HT2A and 5-HT2C receptors on temporal discrimination by mice.Effect of Hallucinogens on Unconditioned Behavior.Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775).Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications.Positive regulation of raphe serotonin neurons by serotonin 2B receptors.Unifying Theories of Psychedelic Drug Effects.Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats.Ebselen has lithium-like effects on central 5-HT2A receptor function."Hallucinations" Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs.An Argument for Amphetamine-Induced Hallucinations in an Invertebrate.Psychedelika : An ancient sacrament for treatment of contemporary psychiatric illness?Psychedelics, Meditation, and Self-Consciousness

P2860

Q24174843-372AA963-1A4F-4814-BBCD-2E0F2CF5F776 Q26746133-34503EC9-262A-4EE9-A4FD-388606DF5570 Q26746137-F4468822-416C-4A73-80BE-4D4CA9A67153 Q30358201-FACCCB2E-4162-4D5D-A2F0-CE377AB7CCD8 Q30359998-AC39DC20-CCF4-4687-ADCC-F26FD0760C8C Q30401421-108ED5A6-39CA-4FAC-9890-1CAEDBB376AF Q30402789-D110A77B-59D5-437F-9889-48C27B62DE75 Q30843010-33768A13-0FC6-4FBF-937C-5CF4839EDE13 Q33577499-A18D42B0-FADF-4E72-AED7-43461C9FCF4C Q33881804-39F3A0F9-344B-4A92-8640-AF3E4810AA3B Q34497649-985FF40F-EFC4-4FE6-99DC-00EAB1CBD468 Q34524116-28F13CEB-FC9F-4B80-8A7D-DD6E1514E79E Q34535259-B39A108B-9BA1-41C8-A0D7-5B6F998EDCB1 Q34546304-26B42DE9-AE41-48AD-83DB-C43D6888DEE5 Q34667835-A79CC541-7168-4663-BA0B-F0FD16E0A936 Q35024752-DC2B5EF1-D684-40CC-BABF-A4A53993F665 Q36844764-36DE25B2-EA2D-4C53-A3AD-3AB1736B9472 Q37306537-522116C4-B1B1-4CCE-A0D3-7270E3D4729E Q38600048-9A6FA41C-9EB2-49A8-9579-A067B90EF10D Q38733778-2CDF0933-7E90-414A-A7C7-1217F301EB58 Q38794300-86FD23E4-1975-4061-A21A-FA38FA7D1404 Q39093171-220855BD-D62A-43E2-987A-E11916D5A9A8 Q39370168-617164C4-C418-4DEF-96D6-45D0CA9FE092 Q39414464-9BDE283D-6BB9-473C-B29E-5031EAB5B913 Q39834312-493FB6AC-98E1-4CD4-9BD9-4CD00F42BECA Q40717603-E14A385D-0E9F-4E4F-9BF3-C10A8E8983F2 Q41842170-E6C2D58F-2144-43F8-8A0E-9103B11A0DDC Q42025447-5A9C96D3-1D4D-46B7-A6C6-CB41DB842C86 Q45279141-F8B13D1D-C189-4EBD-A7B3-494EFE90FF45 Q46573497-3DAE2A94-9022-4983-BD7A-2CB9AD377384 Q47690853-325C94C0-B84A-4F20-8C48-163B8D98C148 Q49912053-65BCDF14-5A97-48A4-ADA3-CC266C7B62DD Q52641641-E9D7D26A-4200-4D00-8625-DB38B42376B1 Q53080749-698731AA-05ED-480E-9683-19C671D4226F Q53445382-8E150D61-CC77-4E46-A28A-462357710A5E Q55058151-DF486489-E6CC-4AF9-AA37-5465719C80E1 Q55516348-A7268CCC-E771-40EE-83E5-3D80C19B90AB Q56638625-1DEE7BC1-71CD-4D29-B212-EC6135BBF9AD Q56852531-F45C67E9-5550-4F34-B4EA-58D3DA25849C Q58764595-2A254862-503E-4A31-9E56-2D4360E1F1E7

P2860

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

http://www.wikidata.org/entity/Q27027381

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

@ast

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

@en

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

@nl

type

label

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

@ast

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

@en

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

@nl

prefLabel

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

@ast

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

@en

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

@nl

P1433

Q27027381-4536AF19-D35D-4EDD-9458-A87E2E2D9A8B

P1476

Q27027381-639F6E9E-1371-4E03-A951-13F13CFCF60C

P2093

Q27027381-089486EC-65E5-46AF-8F55-D50E91E6EBCC

P2860

Q27027381-00A803F8-3D54-4B2E-AFD4-3423ABE983AE

Q27027381-01DE9499-AF9B-45E7-A3BD-7D34A9718AB3

Q27027381-01F107B5-9271-4E9D-9A03-601A11E62C4F

Q27027381-02726448-5A19-4823-88C1-B3DB1394584A

Q27027381-03E30343-FA10-43F9-A1A9-CB1773E4662B

Q27027381-042E4578-ED51-4131-AEE6-847690A968E9

Q27027381-05470C41-11AF-41CC-9500-8F8CE1DE5D2C

Q27027381-065193FE-988C-4E4F-BB75-C417F94A188C

Q27027381-06F81AAA-C9D8-4737-A84F-3308D338EB79

Q27027381-073053EC-3124-4CD4-AAA7-03C5C75A9F49

P304

Q27027381-BD25F0E3-C551-41EC-AEE6-46A2C2D07E11

P31

Q27027381-92815798-51B3-4CA3-81A3-B22CC6935C00

P3181

Q27027381-D0D99B9D-98C7-4CE1-9D9B-91BE1CE8121B

P356

Q27027381-66A32E74-2DDA-4027-9389-C21C991A0BD4

P407

Q27027381-480DDB13-5350-4E9A-B0A9-1ED79BCF7295

P478

Q27027381-DE00024B-E4B5-4B0F-A02B-41C296E8C490

P577

Q27027381-FD603DA3-CA28-4762-B3D1-D375945ADFB7

P698

Q27027381-973CC0C1-A136-43B0-903D-3078257FAD86

P921

Q27027381-7EECF495-E43E-4FA3-9283-2D81BBFF36B4

Q27027381-F8DA32F6-EEC8-42EC-B795-7317736D6212

P932

Q27027381-46194EC1-B293-49C8-A967-E6DB9957418E

P3181

P356

J.BBR.2014.07.016

P1433

Behavioural Brain Research

P1476

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

@en

P2093

Adam L Halberstadt

http://www.w3.org/2001/XMLSchema#string

P2860

Psychometric evaluation of the altered states of consciousness rating scale (OAV)

Lysergamides of Isomeric 2,4-Dimethylazetidines Map the Binding Orientation of the Diethylamide Moiety in the Potent Hallucinogenic Agent N , N -Diethyllysergamide (LSD)

Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis

Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor

Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells

A default mode of brain function

Two kinds of tryptamine receptor

Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A·mGlu2) receptor heteromerization and its psychoactive behavioral function

Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice

The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator

P304

99-120

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3686253

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.BBR.2014.07.016

http://www.w3.org/2001/XMLSchema#string

P407

P478

277

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25036425

http://www.w3.org/2001/XMLSchema#string

P921

Acid lisergic dietilamid

P932

4642895

http://www.w3.org/2001/XMLSchema#string